Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1949

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1C
Chunk 1949
---
 Price Requirement and apply to transfer its listing to the Nasdaq Capital Market on or prior to January 22, 2025. The Company is also
required to satisfy the $2.5 million stockholders’ equity requirement of the Nasdaq Capital Market on or prior to April 22, 2025,
submit certain plans to Nasdaq and make certain disclosures.

On February 12, 2025, we
received a letter from Nasdaq confirming that we have regained compliance with the Bid Price Requirement and we have been moved to the
Nasdaq Capital Market, as required by the Nasdaq Panel.

Regaining compliance with the Bid Price Requirement is one of the conditions
set forth by the Nasdaq Panel in its previously disclosed decision granting our request for an extension to regain compliance with certain
Nasdaq continued listing requirements until April 22, 2025. We continue to make progress towards satisfaction of the other conditions.
Nevertheless, as of the date of this Annual Report, the trading price of our Common Stock is below the Bid Price Requirement and we have
not satisfied the $2.5 million stockholder’s equity requirement. We cannot assure you that we will obtain compliance with these
requirements in a timely manner, or at all.

Warrant Issuances

On December 23, 2024, the Company issued warrants to purchase an aggregate
of 84,061 shares of Common Stock, with an exercise price of $5.61 per share, which was the closing price of the Common Stock on Nasdaq
on December 20, 2024, to certain institutional investors as a condition to the exercise of Preferred Warrants held thereby. On January
6, 2025, the Company issued additional warrants to purchase an aggregate of 163,853 shares of Common Stock, with an exercise price of
$5.82 per share, which was the closing price of the Common Stock on Nasdaq on January 3, 2025, to an institutional investor as a condition
to the exercise of Preferred Warrants held thereby. Such number of shares gives effect to the Reverse Stock Split.

Results of Operations

Revenue

Predecessor and the Company
have not recognized any revenue from any sources, including from product sales, and the Company does not expect to generate any revenue
from the sale of products in the foreseeable future. If the development efforts for the Company’s product candidates, each of which
is a specific product and indication combination, are successful and result in regulatory approval, or if the